vs
Apellis Pharmaceuticals, Inc.（APLS）与TRIMAS CORP（TRS）财务数据对比。点击上方公司名可切换其他公司
TRIMAS CORP的季度营收约是Apellis Pharmaceuticals, Inc.的1.3倍（$256.5M vs $199.9M），TRIMAS CORP净利率更高（31.9% vs -29.5%，领先61.3%），TRIMAS CORP同比增速更快（3.8% vs -5.9%），TRIMAS CORP自由现金流更多（$36.8M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 3.3%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Trimas Corp是一家多元化工业制造企业，设计、生产和销售专业紧固件、航空航天部件、定制包装解决方案、消费及工业五金等工程产品，核心服务航空、汽车、建筑、消费品等领域，业务主要覆盖北美及部分全球市场。
APLS vs TRS — 直观对比
营收规模更大
TRS
是对方的1.3倍
$199.9M
营收增速更快
TRS
高出9.8%
-5.9%
净利率更高
TRS
高出61.3%
-29.5%
自由现金流更多
TRS
多$51.1M
$-14.3M
两年增速更快
APLS
近两年复合增速
3.3%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $256.5M |
| 净利润 | $-59.0M | $81.7M |
| 毛利率 | — | 12.8% |
| 营业利润率 | -25.6% | 5.7% |
| 净利率 | -29.5% | 31.9% |
| 营收同比 | -5.9% | 3.8% |
| 净利润同比 | -62.2% | 236.9% |
| 每股收益（稀释后） | $-0.40 | $2.03 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSTRS
| Q1 26 | — | $256.5M | ||
| Q4 25 | $199.9M | $-140.0M | ||
| Q3 25 | $458.6M | $269.3M | ||
| Q2 25 | $178.5M | $274.8M | ||
| Q1 25 | $166.8M | $241.7M | ||
| Q4 24 | $212.5M | $-66.2M | ||
| Q3 24 | $196.8M | $229.4M | ||
| Q2 24 | $199.7M | $240.5M |
净利润APLSTRS
| Q1 26 | — | $81.7M | ||
| Q4 25 | $-59.0M | $81.7M | ||
| Q3 25 | $215.7M | $9.3M | ||
| Q2 25 | $-42.2M | $16.7M | ||
| Q1 25 | $-92.2M | $12.4M | ||
| Q4 24 | $-36.4M | $5.6M | ||
| Q3 24 | $-57.4M | $2.5M | ||
| Q2 24 | $-37.7M | $10.9M |
毛利率APLSTRS
| Q1 26 | — | 12.8% | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 12.8% | ||
| Q2 25 | — | 13.8% | ||
| Q1 25 | — | 13.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 15.4% | ||
| Q2 24 | — | 14.4% |
营业利润率APLSTRS
| Q1 26 | — | 5.7% | ||
| Q4 25 | -25.6% | — | ||
| Q3 25 | 48.7% | 6.2% | ||
| Q2 25 | -18.6% | 9.9% | ||
| Q1 25 | -50.0% | 9.0% | ||
| Q4 24 | -12.3% | — | ||
| Q3 24 | -24.0% | 3.6% | ||
| Q2 24 | -14.7% | 7.4% |
净利率APLSTRS
| Q1 26 | — | 31.9% | ||
| Q4 25 | -29.5% | -58.4% | ||
| Q3 25 | 47.0% | 3.5% | ||
| Q2 25 | -23.6% | 6.1% | ||
| Q1 25 | -55.3% | 5.1% | ||
| Q4 24 | -17.1% | -8.5% | ||
| Q3 24 | -29.2% | 1.1% | ||
| Q2 24 | -18.9% | 4.5% |
每股收益（稀释后）APLSTRS
| Q1 26 | — | $2.03 | ||
| Q4 25 | $-0.40 | $2.01 | ||
| Q3 25 | $1.67 | $0.23 | ||
| Q2 25 | $-0.33 | $0.41 | ||
| Q1 25 | $-0.74 | $0.30 | ||
| Q4 24 | $-0.30 | $0.14 | ||
| Q3 24 | $-0.46 | $0.06 | ||
| Q2 24 | $-0.30 | $0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $30.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $705.6M |
| 总资产 | $1.1B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSTRS
| Q1 26 | — | $30.0M | ||
| Q4 25 | $466.2M | $30.0M | ||
| Q3 25 | $479.2M | $33.6M | ||
| Q2 25 | $370.0M | $30.3M | ||
| Q1 25 | $358.4M | $32.7M | ||
| Q4 24 | $411.3M | $23.1M | ||
| Q3 24 | $396.9M | $26.9M | ||
| Q2 24 | $360.1M | $35.0M |
总债务APLSTRS
| Q1 26 | — | — | ||
| Q4 25 | — | $469.2M | ||
| Q3 25 | — | $407.1M | ||
| Q2 25 | — | $424.5M | ||
| Q1 25 | — | $434.2M | ||
| Q4 24 | — | $398.1M | ||
| Q3 24 | — | $409.9M | ||
| Q2 24 | — | $427.4M |
股东权益APLSTRS
| Q1 26 | — | $705.6M | ||
| Q4 25 | $370.1M | $705.6M | ||
| Q3 25 | $401.2M | $725.0M | ||
| Q2 25 | $156.3M | $715.3M | ||
| Q1 25 | $164.2M | $686.6M | ||
| Q4 24 | $228.5M | $667.3M | ||
| Q3 24 | $237.1M | $682.8M | ||
| Q2 24 | $264.3M | $675.9M |
总资产APLSTRS
| Q1 26 | — | $1.5B | ||
| Q4 25 | $1.1B | $1.5B | ||
| Q3 25 | $1.1B | $1.4B | ||
| Q2 25 | $821.4M | $1.4B | ||
| Q1 25 | $807.3M | $1.4B | ||
| Q4 24 | $885.1M | $1.3B | ||
| Q3 24 | $901.9M | $1.4B | ||
| Q2 24 | $904.5M | $1.4B |
负债/权益比APLSTRS
| Q1 26 | — | — | ||
| Q4 25 | — | 0.66× | ||
| Q3 25 | — | 0.56× | ||
| Q2 25 | — | 0.59× | ||
| Q1 25 | — | 0.63× | ||
| Q4 24 | — | 0.60× | ||
| Q3 24 | — | 0.60× | ||
| Q2 24 | — | 0.63× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $117.5M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $36.8M |
| 自由现金流率自由现金流/营收 | -7.1% | 14.4% |
| 资本支出强度资本支出/营收 | 0.1% | 18.9% |
| 现金转化率经营现金流/净利润 | — | 1.44× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $109.7M |
8季度趋势，按日历期对齐
经营现金流APLSTRS
| Q1 26 | — | $117.5M | ||
| Q4 25 | $-14.2M | $41.5M | ||
| Q3 25 | $108.5M | $36.5M | ||
| Q2 25 | $4.4M | $30.3M | ||
| Q1 25 | $-53.4M | $9.2M | ||
| Q4 24 | $19.4M | $27.1M | ||
| Q3 24 | $34.1M | $22.0M | ||
| Q2 24 | $-8.3M | $18.4M |
自由现金流APLSTRS
| Q1 26 | — | $36.8M | ||
| Q4 25 | $-14.3M | $36.8M | ||
| Q3 25 | $108.3M | $22.8M | ||
| Q2 25 | $4.4M | $13.2M | ||
| Q1 25 | $-53.4M | $-3.8M | ||
| Q4 24 | $19.3M | $12.1M | ||
| Q3 24 | — | $10.2M | ||
| Q2 24 | $-8.4M | $7.5M |
自由现金流率APLSTRS
| Q1 26 | — | 14.4% | ||
| Q4 25 | -7.1% | -26.3% | ||
| Q3 25 | 23.6% | 8.5% | ||
| Q2 25 | 2.5% | 4.8% | ||
| Q1 25 | -32.0% | -1.6% | ||
| Q4 24 | 9.1% | -18.3% | ||
| Q3 24 | — | 4.4% | ||
| Q2 24 | -4.2% | 3.1% |
资本支出强度APLSTRS
| Q1 26 | — | 18.9% | ||
| Q4 25 | 0.1% | -3.4% | ||
| Q3 25 | 0.0% | 5.1% | ||
| Q2 25 | 0.0% | 6.2% | ||
| Q1 25 | 0.0% | 5.4% | ||
| Q4 24 | 0.0% | -22.6% | ||
| Q3 24 | 0.0% | 5.2% | ||
| Q2 24 | 0.0% | 4.5% |
现金转化率APLSTRS
| Q1 26 | — | 1.44× | ||
| Q4 25 | — | 0.51× | ||
| Q3 25 | 0.50× | 3.92× | ||
| Q2 25 | — | 1.81× | ||
| Q1 25 | — | 0.74× | ||
| Q4 24 | — | 4.80× | ||
| Q3 24 | — | 8.71× | ||
| Q2 24 | — | 1.68× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
TRS
暂无分部数据
